Multiple Myeloma
Conditions
Brief summary
Response (≥VGPR) after 8 cycles of DVCd
Detailed description
Minimal residual disease (MRD) negativity at any time before and during maintenance therapy (DVd) assessed by NGS at a level of 10e-5, Progression-free survival at 12 months from start of second line therapy, Progression-free survival from trial inclusion (PFS), Time to next treatment (TTNT), Overall survival (OS), Overall response rate of first line treatment, Overall response rate of second line treatment, Minimal residual disease (MRD) negativity at any time before and during maintenance therapy (DVd) assessed by NGS at other thresholds or by Flow
Interventions
DRUGDARZALEX 1800 mg solution for injection
Sponsors
University Of Cologne
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response (≥VGPR) after 8 cycles of DVCd | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimal residual disease (MRD) negativity at any time before and during maintenance therapy (DVd) assessed by NGS at a level of 10e-5, Progression-free survival at 12 months from start of second line therapy, Progression-free survival from trial inclusion (PFS), Time to next treatment (TTNT), Overall survival (OS), Overall response rate of first line treatment, Overall response rate of second line treatment, Minimal residual disease (MRD) negativity at any time before and during maintenance therapy (DVd) assessed by NGS at other thresholds or by Flow | — |
Countries
Germany
Outcome results
None listed